Lisa Nolan - Net Worth and Insider Trading

Lisa Nolan Net Worth

The estimated net worth of Lisa Nolan is at least $3,265 dollars as of 2024-05-24. Lisa Nolan is the Chief Business Officer of Rexahn Pharmaceuticals Inc and owns about 451 shares of Rexahn Pharmaceuticals Inc (REXN) stock worth over $3,265. Details can be seen in Lisa Nolan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Lisa Nolan has not made any transactions after 2019-01-30 and currently still holds the listed stock(s).

Transaction Summary of Lisa Nolan

Lisa Nolan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Lisa Nolan owns 3 companies in total, including Rexahn Pharmaceuticals Inc (REXN) , Relmada Therapeutics Inc (RLMD) , and Ocuphire Pharma Inc (OCUP) .

Click here to see the complete history of Lisa Nolan’s form 4 insider trades.

Insider Ownership Summary of Lisa Nolan

Ticker	Comapny	Transaction Date	Type of Owner
REXN	Rexahn Pharmaceuticals Inc	2019-02-28	Chief Business Officer
RLMD	Relmada Therapeutics Inc	2015-12-14	Chief Business Officer
OCUP	Ocuphire Pharma Inc	2016-07-06	Chief Business Officer

Lisa Nolan Latest Holdings Summary

Lisa Nolan currently owns a total of 1 stock. Lisa Nolan owns 451 shares of Rexahn Pharmaceuticals Inc (REXN) as of January 30, 2019, with a value of $3,265.

Latest Holdings of Lisa Nolan

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
REXN	Rexahn Pharmaceuticals Inc	2019-01-30	451	7.24	3,265

Holding Weightings of Lisa Nolan

Lisa Nolan Form 4 Trading Tracker

According to the SEC Form 4 filings, Lisa Nolan has made a total of 0 transactions in Rexahn Pharmaceuticals Inc (REXN) over the past 5 years. The most-recent trade in Rexahn Pharmaceuticals Inc is the acquisition of 417 shares on January 30, 2019, which cost Lisa Nolan around $13,000.

Insider Trading History of Lisa Nolan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Lisa Nolan Trading Performance

GuruFocus tracks the stock performance after each of Lisa Nolan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Lisa Nolan is -21.3%. GuruFocus also compares Lisa Nolan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Lisa Nolan within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Lisa Nolan's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Lisa Nolan

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-16.83
Relative Return to S&P 500(%)	-21.4

Lisa Nolan Ownership Network

Ownership Network List of Lisa Nolan

No Data

Ownership Network Relation of Lisa Nolan

Lisa Nolan Owned Company Details

What does Rexahn Pharmaceuticals Inc do?

Who are the key executives at Rexahn Pharmaceuticals Inc?

Lisa Nolan is the Chief Business Officer of Rexahn Pharmaceuticals Inc. Other key executives at Rexahn Pharmaceuticals Inc include Chief Medical Officer Ely Benaim , director & President and CEO Douglas J Swirsky , and director & Chief Executive Officer Peter David Suzdak .

Rexahn Pharmaceuticals Inc (REXN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Rexahn Pharmaceuticals Inc (REXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Rexahn Pharmaceuticals Inc (REXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Rexahn Pharmaceuticals Inc (REXN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rexahn Pharmaceuticals Inc Insider Transactions

No Available Data

What does Relmada Therapeutics Inc do?

Who are the key executives at Relmada Therapeutics Inc?

Lisa Nolan is the Chief Business Officer of Relmada Therapeutics Inc. Other key executives at Relmada Therapeutics Inc include director & Chief Executive Officer Sergio Traversa , Chief Financial Officer Chuck Ence , and Chief Medical Officer Cedric O'gorman .

Relmada Therapeutics Inc (RLMD) Insider Trades Summary

Over the past 18 months, Lisa Nolan made no insider transaction in Relmada Therapeutics Inc (RLMD). Other recent insider transactions involving Relmada Therapeutics Inc (RLMD) include a net purchase of 155,250 shares made by Sergio Traversa , a net purchase of 38,970 shares made by Chuck Ence , and a net purchase of 32,675 shares made by Maged Shenouda .

In summary, during the past 3 months, insiders sold 0 shares of Relmada Therapeutics Inc (RLMD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Relmada Therapeutics Inc (RLMD) were sold and 236,895 shares were bought by its insiders, resulting in a net purchase of 236,895 shares.

Relmada Therapeutics Inc (RLMD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Relmada Therapeutics Inc Insider Transactions

No Available Data

What does Ocuphire Pharma Inc do?

Who are the key executives at Ocuphire Pharma Inc?

Lisa Nolan is the Chief Business Officer of Ocuphire Pharma Inc. Other key executives at Ocuphire Pharma Inc include Chief Executive Officer George Magrath , SVP & Operations & Bus. Dev. Ronil A. Patel , and director & President and CEO Mina Sooch .

Ocuphire Pharma Inc (OCUP) Insider Trades Summary

Over the past 18 months, Lisa Nolan made no insider transaction in Ocuphire Pharma Inc (OCUP). Other recent insider transactions involving Ocuphire Pharma Inc (OCUP) include a net purchase of 30,000 shares made by George Magrath , and a net purchase of 2,000 shares made by .

In summary, during the past 3 months, insiders sold 0 shares of Ocuphire Pharma Inc (OCUP) in total and bought 42,000 shares, with a net purchase of 42,000 shares. During the past 18 months, 0 shares of Ocuphire Pharma Inc (OCUP) were sold and 42,000 shares were bought by its insiders, resulting in a net purchase of 42,000 shares.

Ocuphire Pharma Inc (OCUP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ocuphire Pharma Inc Insider Transactions

No Available Data

Lisa Nolan Mailing Address

Above is the net worth, insider trading, and ownership report for Lisa Nolan. You might contact Lisa Nolan via mailing address: 36 Rockland Mills, Rockland De 19732.

Discussions on Lisa Nolan

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.